Loading company…
Ring Therapeutics develops gene therapy vectors using human commensal anelloviruses.
Founded in 2017 in Massachusetts by Avak Kahvejian, Erica Weinstein, and Noubar Afeyan, Ring Therapeutics develops gene therapy products using human commensal viromes. Its Anellogy platform uses anelloviruses to create vectors intended to deliver treatments to specific tissues, and Anelloscope detects and tracks anelloviruses. In October 2022, the company raised USD 71.50 million in Series C funding from Alexandria Venture Investments, CJ Investment Partners LLC, and Kyowa Kirin, at a USD 561.16 million post-money valuation. Christopher McNulty is CEO as of 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in